Abstract
Obesity is the epidemic challenging our society from a medical as well as an economic perspective. The prevalence of obesity leading to decreased life expectancy due to, e.g., cardiovascular disease is dramatically escalating. In the UK, for instance, rates of obese (body-mass index ≥30 kg/m2) have increased by 30% in women, 40% in men, and 50% in children within the last decade resulting in 23% of adults being obese in 2007 and a prognosis of 50% for 2050 [1]. The causes underlying the obesity epidemic are still not entirely understood, but its consequences are already apparent, e.g. by the dramatic increase in type 2 diabetes (T2DM), a disease complicated by increased risk of macrovascular and microvascular disease, nowadays even occurring in children [2].
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
(2007) Time to supersize control efforts for obesity. Lancet 370:1521
Weiss R, Dziura J, Burgert TS et al (2004) Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 350:2362–2374
Pi-Sunyer FX (1993) Medical hazards of obesity. Ann Intern Med 119:655–660
Zimmet P, Alberti KG, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414:782–787
Despres JP, Lemieux I (2006) Abdominal obesity and metabolic syndrome. Nature 444:881–887
Zeyda M, Stulnig TM (2009) Obesity, inflammation, and insulin resistance–a mini-review. Gerontology 55:379–386
Imrie H, Abbas A, Kearney M (2010) Insulin resistance, lipotoxicity and endothelial dysfunction. Biochim Biophys Acta 1801:320–326
Booth GL, Kapral MK, Fung K, Tu JV (2006) Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 368:29–36
Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB (1999) Elevated C-reactive protein levels in overweight and obese adults. JAMA 282:2131–2135
Lemieux I, Pascot A, Prud’homme D et al (2001) Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 21:961–967
Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM (1995) Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95:2409–2415
Roytblat L, Rachinsky M, Fisher A et al (2000) Raised interleukin-6 levels in obese patients. Obes Res 8:673–675
Christiansen T, Richelsen B, Bruun JM (2005) Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. Int J Obes (Lond) 29:146–150
Straczkowski M, Dzienis-Straczkowska S, Stepien A et al (2002) Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factor-alpha system. J Clin Endocrinol Metab 87:4602–4606
Gomez-Ambrosi J, Catalan V, Ramirez B et al (2007) Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J Clin Endocrinol Metab 92:3719–3727
Kiefer FW, Zeyda M, Todoric J et al (2008) Osteopontin expression in human and murine obesity: extensive local up-regulation in adipose tissue but minimal systemic alterations. Endocrinology 149:1350–1357
Friedman JM, Halaas JL (1998) Leptin and the regulation of body weight in mammals. Nature 395:763–770
Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444:860–867
Karalis KP, Giannogonas P, Kodela E et al (2009) Mechanisms of obesity and related pathology: linking immune responses to metabolic stress. FEBS J 276:5747–5754
Hutley L, Prins JB (2005) Fat as an endocrine organ: relationship to the metabolic syndrome. Am J Med Sci 330:280–289
Maeda K, Okubo K, Shimomura I et al (1997) Analysis of an expression profile of genes in the human adipose tissue. Gene 190:227–235
Rabe K, Lehrke M, Parhofer KG, Broedl UC (2008) Adipokines and insulin resistance. Mol Med 14:741–751
Hajer GR, van Haeften TW, Visseren FLJ (2008) Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 29:2959–2971
Zeyda M, Stulnig TM (2007) Adipose tissue macrophages. Immunol Lett 112:61–67
Baffy G (2009) Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J Hepatol 21(1):212–223
Olefsky JM, Glass CK (2010) Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 72:219–246
Sell H, Eckel J (2010) Adipose tissue inflammation: novel insight into the role of macrophages and lymphocytes. Curr Opin Clin Nutr Metab Care 13:366–370
Gregor MF, Hotamisligil GS (2007) Thematic review series: Adipocyte Biology. Adipocyte stress: the endoplasmic reticulum and metabolic disease. J Lipid Res 48:1905–1914
Zeyda M, Gollinger K, Kriehuber E et al (2010) Newly identified adipose tissue macrophage populations in obesity with distinct chemokine and chemokine receptor expression. Int J Obes (Lond) 34:1684–1694
Curat CA, Miranville A, Sengenes C et al (2004) From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes. Diabetes 53:1285–1292
Hotamisligil GS (2005) Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes. Diabetes 54(Suppl 2):S73–S78
Petersen KF, Shulman GI (2006) Etiology of insulin resistance. Am J Med 119:S10–S16
de Luca C, Olefsky JM (2008) Inflammation and insulin resistance. FEBS Lett 582:97–105
Suganami T, Tanimoto-Koyama K, Nishida J et al (2007) Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol 27:84–91
Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116:1793–1801
Madala MC, Franklin BA, Chen AY et al (2008) Obesity and age of first non-ST-segment elevation myocardial infarction. J Am Coll Cardiol 52:979–985
Rocha VZ, Libby P (2009) Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol 6:399–409
Libby P (2002) Inflammation in atherosclerosis. Nature 420:868–874
Glynn RJ, MacFadyen JG, Ridker PM (2009) Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study. Clin Chem 55:305–312
Libby P, Okamoto Y, Rocha VZ, Folco E (2010) Inflammation in atherosclerosis: transition from theory to practice. Circ J 74:213–220
Ohman MK, Shen Y, Obimba CI et al (2008) Visceral adipose tissue inflammation accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation 117:798–805
Calabrò P, Golia E, Maddaloni V et al (2009) Adipose tissue-mediated inflammation: the missing link between obesity and cardiovascular disease? Intern Emerg Med 4:25–34
Rajsheker S, Manka D, Blomkalns AL et al (2010) Crosstalk between perivascular adipose tissue and blood vessels. Curr Opin Pharmacol 10:191–196
Fain JN, Sacks HS, Bahouth SW et al (2010) Human epicardial adipokine messenger RNAs: comparisons of their expression in substernal, subcutaneous, and omental fat. Metabolism 59:1379–1386
Verhagen SN, Visseren FLJ (2011) Perivascular adipose tissue as a cause of atherosclerosis. Atherosclerosis 214:3–10
Friedman JM, Halaas JL (1998) Leptin and the regulation of body weight in mammals. Nature 395:763–770
Niswender KD, Magnuson MA (2007) Obesity and the beta cell: lessons from leptin. J Clin Invest 117:2753–2756
Kieffer TJ, Habener JF (2000) The adipoinsular axis: effects of leptin on pancreatic beta -cells. Am J Physiol 278:E1–E14
Munzberg H, Myers MG (2005) Molecular and anatomical determinants of central leptin resistance. Nat Neurosci 8:566–570
Lam QL, Lu L (2007) Role of leptin in immunity. Cell Mol Immunol 4:1–13
Fernandez-Riejos P, Najib S, Santos-Alvarez J et al (2010) Role of leptin in the activation of immune cells. Mediators Inflamm 2010:568343
Sweeney G (2010) Cardiovascular effects of leptin. Nat Rev Cardiol 7:22–29
Singh M, Bedi US, Singh PP, Arora R, Khosla S (2010) Leptin and the clinical cardiovascular risk. Int J Cardiol 140:266–271
Singh P, Peterson TE, Barber KR et al (2010) Leptin upregulates the expression of plasminogen activator inhibitor-1 in human vascular endothelial cells. Biochem Biophys Res Commun 392:47–52
Hu E, Liang P, Spiegelman BM (1996) AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271:10697–10703
Arita Y, Kihara S, Ouchi N et al (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79–83
Hotta K, Funahashi T, Bodkin NL et al (2001) Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50:1126–1133
Weyer C, Funahashi T, Tanaka S et al (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930–1935
Tschritter O, Fritsche A, Thamer C et al (2003) Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 52:239–243
Hanley AJG, Bowden D, Wagenknecht LE et al (2007) Associations of adiponectin with body Fat distribution and insulin sensitivity in nondiabetic Hispanics and African-Americans. J Clin Endocrinol Metab 92:2665–2671
Pajvani UB, Hawkins M, Combs TP et al (2004) Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279:12152–12162
Yamauchi T, Nio Y, Maki T et al (2007) Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13:332–339
Okamoto M, Ohara-Imaizumi M, Kubota N et al (2008) Adiponectin induces insulin secretion in vitro and in vivo at a low glucose concentration. Diabetologia 51:827–835
Kubota N, Yano W, Kubota T et al (2007) Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab 6:55–68
Folco EJ, Rocha VZ, López-Ilasaca M, Libby P (2009) Adiponectin inhibits pro-inflammatory signaling in human macrophages independent of interleukin-10. J Biol Chem 284:25569–25575
Lovren F, Pan Y, Quan A et al (2010) Adiponectin primes human monocytes into alternative anti-inflammatory M2 macrophages. Am J Physiol Heart Circ Physiol 299(3):H656–H663, ajpheart.00115.02010
Tilg H, Wolf AM (2005) Adiponectin: a key fat-derived molecule regulating inflammation. Expert Opin Ther Targets 9:245–251
Yamauchi T, Kamon J, Waki H et al (2003) Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278:2461–2468
Luo N, Liu J, Chung BH et al (2010) Macrophage adiponectin expression improves insulin sensitivity and protects against inflammation and atherosclerosis. Diabetes 59:791–799
Okamoto Y, Folco EJ, Minami M et al (2008) Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ Res 102:218–225
de Souza Batista CM, Yang RZ, Lee MJ et al (2007) Omentin plasma levels and gene expression are decreased in obesity. Diabetes 56:1655–1661
Yang RZ, Lee MJ, Hu H et al (2006) Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol 290:E1253–E1261
Tan BK, Adya R, Farhatullah S et al (2008) Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome. Diabetes 57:801–808
Schäffler A, Neumeier M, Herfarth H et al (2005) Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta 1732:96–102
Senolt L, Polanská M, Filková M et al (2010) Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis. Ann Rheum Dis 69:1410–1411
Hida K, Wada J, Eguchi J et al (2005) Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 102:10610–10615
Klöting N, Berndt J, Kralisch S et al (2006) Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 339:430–436
Youn B-S, Klöting N, Kratzsch J et al (2008) Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 57:372–377
Loeffelholz Cv, Mohlig M, Arafat AM et al (2010) Circulating vaspin is unrelated to insulin sensitivity in a cohort of nondiabetic humans. Eur J Endocrinol 162:507–513
Seeger J, Ziegelmeier M, Bachmann A et al (2008) Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J Clin Endocrinol Metab 93:247–251
Fukuhara A, Matsuda M, Nishizawa M et al (2005) Visfatin: a protein secreted by visceral Fat that mimics the effects of insulin. Science 307:426–430
Filippatos TD, Derdemezis CS, Gazi IF et al (2008) Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur J Clin Invest 38:71–72
Chen M-P, Chung F-M, Chang D-M et al (2006) Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91:295–299
Oki K, Yamane K, Kamei N, Nojima H, Kohno N (2007) Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin Endocrinol 67:796–800
Berndt J, Klöting N, Kralisch S et al (2005) Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 54:2911–2916
Filippatos TD, Randeva HS, Derdemezis CS, Elisaf MS, Mikhailidis DP (2010) Visfatin/PBEF and atherosclerosis-related diseases. Curr Vasc Pharmacol 8:12–28
Kadoglou NP, Sailer N, Moumtzouoglou A et al (2010) Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 118:75–80
Liu SW, Qiao SB, Yuan JS, Liu DQ (2009) Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf) 71:202–207
Cheng KH, Chu CS, Lee KT et al (2008) Adipocytokines and proinflammatory mediators from abdominal and epicardial adipose tissue in patients with coronary artery disease. Int J Obes (Lond) 32:268–274
Sommer G, Kralisch S, Kloting N et al (2010) Visfatin is a positive regulator of MCP-1 in human adipocytes in vitro and in mice in vivo. Obesity (Silver Spring) 18:1486–1492
Revollo JR, Korner A, Mills KF et al (2007) Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 6:363–375
Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87–91
Bruun JM, Pedersen SB, Richelsen B (2001) Regulation of interleukin 8 production and gene expression in human adipose tissue in vitro. J Clin Endocrinol Metab 86:1267–1273
Rotter V, Nagaev I, Smith U (2003) Interleukin-6 (IL-6) induces insulin resistance in 3 T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-α, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278:45777–45784
Ajuwon KM, Spurlock ME (2005) Palmitate activates the NF-kB transcription factor and induces IL-6 and TNFa expression in 3 T3-L1 adipocytes. J Nutr 135:1841–1846
Hoch M, Eberle AN, Peterli R et al (2008) LPS induces interleukin-6 and interleukin-8 but not tumor necrosis factor-alpha in human adipocytes. Cytokine 41:29–37
Suganami T, Nishida J, Ogawa Y (2005) A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol 25:2062–2068
Wang B, Jenkins JR, Trayhurn P (2005) Expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture: integrated response to TNF-alpha. Am J Physiol 288:E731–E740
Nov O, Kohl A, Lewis EC et al (2010) Interleukin-1{beta} may mediate insulin resistance in liver-derived cells in response to adipocyte inflammation. Endocrinology 151:4247–4256
Weisberg SP, McCann D, Desai M et al (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796–1808
Xu H, Barnes GT, Yang Q et al (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112:1821–1830
Lumeng CN, Maillard I, Saltiel AR (2009) T-ing up inflammation in fat. Nat Med 15:846–847
Anderson EK, Gutierrez DA, Hasty AH (2010) Adipose tissue recruitment of leukocytes. Curr Opin Lipidol 21:172–177
Fain JN (2006) Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm 74:443–477
Zeyda M, Farmer D, Todoric J et al (2007) Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production. Int J Obes (Lond) 31:1420–1428
Mohamed-Ali V, Goodrick S, Rawesh A et al (1997) Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-{alpha}, in vivo. J Clin Endocrinol Metab 82:4196–4200
Bernstein LE, Berry J, Kim S, Canavan B, Grinspoon SK (2006) Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med 166:902–908
Paquot N, Castillo MJ, Lefebvre PJ, Scheen AJ (2000) No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab 85:1316–1319
Dominguez H, Storgaard H, Rask-Madsen C et al (2005) Metabolic and vascular effects of tumor necrosis factor-Î ± blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 42:517–525
Sethi JK, Hotamisligil GS (1999) The role of TNF alpha in adipocyte metabolism. Semin Cell Dev Biol 10:19–29
Xie L, Ortega MT, Mora S, Chapes SK (2010) Interactive changes between macrophages and adipocytes. Clin Vaccine Immunol 17:651–659
Oda E (2008) The metabolic syndrome as a concept of adipose tissue disease. Hypertens Res 31:1283–1291
Franckhauser S, Elias I, Rotter Sopasakis V et al (2008) Overexpression of Il6 leads to hyperinsulinaemia, liver inflammation and reduced body weight in mice. Diabetologia 51(7):1306–1316
Pedersen BK, Febbraio MA (2007) Point: Interleukin-6 does have a beneficial role in insulin sensitivity and glucose homeostasis. J Appl Physiol 102:814–816
Kristiansen OP, Mandrup-Poulsen T (2005) Interleukin-6 and diabetes. Diabetes 54:S114–S124
Dayer JM, Chicheportiche R, Juge-Aubry C, Meier C (2006) Adipose tissue has anti-inflammatory properties: focus on IL-1 receptor antagonist (IL-1Ra). Ann N Y Acad Sci 1069:444–453
Juge-Aubry CE, Somm E, Pernin A et al (2005) Adipose tissue is a regulated source of interleukin-10. Cytokine 29:270–274
den Boer MA, Voshol PJ, Schroder-van der Elst JP et al (2006) Endogenous interleukin-10 protects against hepatic steatosis but does not improve insulin sensitivity during high-fat feeding in mice. Endocrinology 147:4553–4558
Cartier A, Bergeron J, Poirier P et al (2009) Increased plasma interleukin-1 receptor antagonist levels in men with visceral obesity. Ann Med 41(6):471–478
Carstensen M, Herder C, Kivimaki M et al (2010) Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study. Diabetes 59:1222–1227
Saltevo J, Laakso M, Jokelainen J et al (2008) Levels of adiponectin, C-reactive protein and interleukin-1 receptor antagonist are associated with insulin sensitivity: a population-based study. Diabetes Metab Res Rev 24:378–383
Mazzali M, Kipari T, Ophascharoensuk V et al (2002) Osteopontin–a molecule for all seasons. QJM 95:3–13
Standal T, Borset M, Sundan A (2004) Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 26:179–184
Rangaswami H, Bulbule A, Kundu GC (2006) Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16:79–87
Xu G, Nie H, Li N et al (2005) Role of osteopontin in amplification and perpetuation of rheumatoid synovitis. J Clin Invest 115:1060–1067
Teti A, Farina AR, Villanova I et al (1998) Activation of MMP-2 by human GCT23 giant cell tumour cells induced by osteopontin, bone sialoprotein and GRGDSP peptides is RGD and cell shape change dependent. Int J Cancer 77:82–93
Nomiyama T, Perez-Tilve D, Ogawa D et al (2007) Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest 117:2877–2888
Kiefer FW, Zeyda M, Gollinger K et al (2010) Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. Diabetes 59:935–946
Bertola A, Deveaux V, Bonnafous S et al (2009) Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity. Diabetes 58:125–133
Lin YH, Yang-Yen HF (2001) The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem 276:46024–46030
de Kleijn DP, Moll FL, Hellings WE et al (2010) Local atherosclerotic plaques are a source of prognostic biomarkers for adverse cardiovascular events. Arterioscler Thromb Vasc Biol 30:612–619
O’Brien ER, Garvin MR, Stewart DK et al (1994) Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Thromb 14:1648–1656
O’Brien KD, Kuusisto J, Reichenbach DD et al (1995) Osteopontin is expressed in human aortic valvular lesions. Circulation 92:2163–2168
Bruemmer D, Collins AR, Noh G et al (2003) Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest 112:1318–1331
Isoda K, Nishikawa K, Kamezawa Y et al (2002) Osteopontin plays an important role in the development of medial thickening and neointimal formation. Circ Res 91:77–82
Kato R, Momiyama Y, Ohmori R et al (2009) Prognostic significance of plasma osteopontin levels in patients undergoing percutaneous coronary intervention. Circ J 73:152–157
Minoretti P, Falcone C, Calcagnino M et al (2006) Prognostic significance of plasma osteopontin levels in patients with chronic stable angina. Eur Heart J 27:802–807
Rosenberg M, Zugck C, Nelles M et al (2008) Osteopontin, a new prognostic biomarker in patients with chronic heart failure. Circ Heart Fail 1:43–49
Bazzichi L, Ghiadoni L, Rossi A et al (2009) Osteopontin is associated with increased arterial stiffness in rheumatoid arthritis. Mol Med 15:402–406
Kase S, Yokoi M, Saito W et al (2007) Increased osteopontin levels in the vitreous of patients with diabetic retinopathy. Ophthalmic Res 39:143–147
Lai CF, Seshadri V, Huang K et al (2006) An osteopontin-NADPH oxidase signaling cascade promotes pro-matrix metalloproteinase 9 activation in aortic mesenchymal cells. Circ Res 98:1479–1489
Subramanian V, Krishnamurthy P, Singh K, Singh M (2007) Lack of osteopontin improves cardiac function in streptozotocin-induced diabetic mice. Am J Physiol Heart Circ Physiol 292:H673–H683
Massiéra F, Bloch-Faure M, Ceiler D et al (2001) Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 15(14):2727–2729, 01-0457fje
Sata M, Fukuda D (2010) Crucial role of renin-angiotensin system in the pathogenesis of atherosclerosis. J Med Invest 57:12–25
Sarzani R, Marcucci P, Salvi F et al (2007) Angiotensin II stimulates and atrial natriuretic peptide inhibits human visceral adipocyte growth. Int J Obes 32:259–267
Alessi MC, Peiretti F, Morange P et al (1997) Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 46:860–867
Festa A, D’Agostino R, Tracy RP, Haffner SM (2002) Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes. Diabetes 51:1131–1137
Bastelica D, Morange P, Berthet B et al (2002) Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits. Arterioscler Thromb Vasc Biol 22:173–178
Kishore P, Li W, Tonelli J et al (2010) Adipocyte-derived factors potentiate nutrient-induced production of plasminogen activator inhibitor-1 by macrophages. Sci Transl Med 2:20ra15
Steppan CM, Bailey ST, Bhat S et al (2001) The hormone resistin links obesity to diabetes. Nature 409:307–312
Savage DB, Sewter CP, Klenk ES et al (2001) Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 50:2199–2202
Patel L, Buckels AC, Kinghorn IJ et al (2003) Resistin is expressed in human macrophages and directly regulated by PPAR[gamma] activators. Biochem Biophys Res Commun 300:472–476
Yang R-Z, Huang Q, Xu A et al (2003) Comparative studies of resistin expression and phylogenomics in human and mouse. Biochem Biophys Res Commun 310:927–935
Filková M, Haluzík M, Gay S, Senolt L (2009) The role of resistin as a regulator of inflammation: implications for various human pathologies. Clin Immunol 133:157–170
Reilly MP, Lehrke M, Wolfe ML et al (2005) Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111:932–939
Chu S, Ding W, Li K, Pang Y, Tang C (2008) Plasma resistin associated with myocardium injury in patients with acute coronary syndrome. Circ J 72:1249–1253
Jung HS, Park K-H, Cho YM et al (2006) Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res 69:76–85
Lee T-S, Lin C-Y, Tsai J-Y et al (2009) Resistin increases lipid accumulation by affecting class A scavenger receptor, CD36 and ATP-binding cassette transporter-A1 in macrophages. Life Sci 84:97–104
Verma S, Li S-H, Wang C-H et al (2003) Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 108:736–740
Calabro P, Samudio I, Willerson JT, Yeh ETH (2004) Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation 110:3335–3340
von Eynatten M, Humpert PM (2008) Retinol-binding protein-4 in experimental and clinical metabolic disease. Expert Rev Mol Diagn 8:289–299
Yang Q, Graham TE, Mody N et al (2005) Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436:356–362
Graham TE, Yang Q, Bluher M et al (2006) Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 354:2552–2563
Hassink S, Balagopal PB (2009) RBP4: from retinol transporter to biomarker? J Pediatr 154:5–7
Graham TE, Wason CJ, Bluher M, Kahn BB (2007) Shortcomings in methodology complicate measurements of serum retinol binding protein (RBP4) in insulin-resistant human subjects. Diabetologia 50:814–823
Ingelsson E, Lind L (2009) Circulating retinol-binding protein 4 and subclinical cardiovascular disease in the elderly. Diabetes Care 32:733–735
Park SE, Kim DH, Lee JH et al (2009) Retinol-binding protein-4 is associated with endothelial dysfunction in adults with newly diagnosed type 2 diabetes mellitus. Atherosclerosis 204:23–25
Stuck BJ, Kahn BB (2009) Retinol-binding protein 4 (RBP4): a biomarker for subclinical atherosclerosis? Am J Hypertens 22:948–949
Goralski KB, McCarthy TC, Hanniman EA et al (2007) Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 282:28175–28188
Takahashi M, Takahashi Y, Takahashi K et al (2008) Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3 T3-L1 adipocytes. FEBS Lett 582:573–578
Becker M, Rabe K, Lebherz C et al (2010) Expression of human chemerin induces insulin resistance in the skeletal muscle but does not affect weight, lipid levels and atherosclerosis in LDL receptor knockout mice on high fat diet. Diabetes 59:2898–2903
Ernst MC, Issa M, Goralski KB, Sinal CJ (2010) Chemerin exacerbates glucose intolerance in mouse models of obesity and diabetes. Endocrinology 151:1998–2007
Bozaoglu K, Bolton K, McMillan J et al (2007) Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 148:4687–4694
Weigert J, Neumeier M, Wanninger J et al (2010) Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf) 72:342–348
Parlee SD, Ernst MC, Muruganandan S, Sinal CJ, Goralski KB (2010) Serum chemerin levels vary with time of day and are modified by obesity and tumor necrosis factor-{alpha}. Endocrinology 151:2590–2602
Sell H, Divoux A, Poitou C et al (2010) Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J Clin Endocrinol Metab 95:2892–2896
Yang M, Yang G, Dong J et al (2010) Elevated plasma levels of chemerin in newly diagnosed type 2 diabetes mellitus with hypertension. J Investig Med 58:883–886
Bozaoglu K, Segal D, Shields KA et al (2009) Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J Clin Endocrinol Metab 94:3085–3088
Lehrke M, Becker A, Greif M et al (2009) Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol 161:339–344
Hart R, Greaves DR (2010) Chemerin contributes to inflammation by promoting macrophage adhesion to VCAM-1 and fibronectin through clustering of VLA-4 and VLA-5. J Immunol 185:3728–3739
Zabel BA, Allen SJ, Kulig P et al (2005) Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades. J Biol Chem 280:34661–34666
Cash JL, Hart R, Russ A et al (2008) Synthetic chemerin-derived peptides suppress inflammation through ChemR23. J Exp Med 205:767–775
Cash JL, Christian AR, Greaves DR (2010) Chemerin peptides promote phagocytosis in a ChemR23- and Syk-dependent manner. J Immunol 184:5315–5324
Fain JN, Kanu A, Bahouth SW et al (2002) Comparison of PGE2, prostacyclin and leptin release by human adipocytes versus explants of adipose tissue in primary culture. Prostaglandins Leukot Essent Fatty Acids 67:467–473
Horrillo R, Gonzalez-Periz A, Martinez-Clemente M et al (2010) 5-Lipoxygenase activating protein signals adipose tissue inflammation and lipid dysfunction in experimental obesity. J Immunol 184:3978–3987
Nunemaker CS, Chen M, Pei H et al (2008) 12-Lipoxygenase-knockout mice are resistant to inflammatory effects of obesity induced by Western diet. Am J Physiol 295:E1065–E1075
Wittwer J, Hersberger M (2007) The two faces of the 15-lipoxygenase in atherosclerosis. Prostaglandins Leukot Essent Fatty Acids 77:67–77
Hsieh PS, Jin JS, Chiang CF et al (2009) COX-2-mediated inflammation in fat is crucial for obesity-linked insulin resistance and fatty liver. Obesity (Silver Spring) 17:1150–1157
Hsieh PS, Lu KC, Chiang CF, Chen CH (2010) Suppressive effect of COX2 inhibitor on the progression of adipose inflammation in high-fat-induced obese rats. Eur J Clin Invest 40:164–171
Koska J, Ortega E, Bunt JC et al (2009) The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. Diabetologia 52:385–393
Serhan CN (2008) Controlling the resolution of acute inflammation: a new genus of dual anti-inflammatory and proresolving mediators. J Periodontol 79:1520–1526
Serhan CN (2007) Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol 25:101–137
Merched AJ, Ko K, Gotlinger KH, Serhan CN, Chan L (2008) Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J 22:3595–3606
Todoric J, Loffler M, Huber J et al (2006) Adipose tissue inflammation induced by high-fat diet in obese diabetic mice is prevented by n-3 polyunsaturated fatty acids. Diabetologia 49:2109–2119
Zeyda M, Stulnig TM (2009) Dietary fatty acids as modulators of adipose tissue inflammation. In: Awad AB, Bradford PG (eds) Adipose tissue and inflammation. CRC Press, Boca Raton, pp 189–204. ISBN 978-1-4200-9130-4
Breslow JL (2006) n-3 Fatty acids and cardiovascular disease. Am J Clin Nutr 83:S1477–S1482
Gonzalez-Periz A, Horrillo R, Ferre N et al (2009) Obesity-induced insulin resistance and hepatic steatosis are alleviated by {omega}-3 fatty acids: a role for resolvins and protectins. FASEB J 23:1946–1957
Li S, Sun Y, Liang C-P et al (2009) Defective phagocytosis of apoptotic cells by macrophages in atherosclerotic lesions of ob/ob mice and reversal by a fish oil diet. Circ Res 105:1072–1082
Tsuchida A, Yamauchi T, Takekawa S et al (2005) Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes 54:3358–3370
Nakamachi T, Nomiyama T, Gizard F et al (2007) PPARalpha agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes. Diabetes 56:1662–1670
Toyoda T, Kamei Y, Kato H et al (2008) Effect of peroxisome proliferator-activated receptor-alpha ligands in the interaction between adipocytes and macrophages in obese adipose tissue. Obesity (Silver Spring) 16(6):1199–1207
Gonzalez-Periz A, Claria J (2010) Resolution of adipose tissue inflammation. Sci World J 10:832–856
Lidell ME, Enerback S (2010) Brown adipose tissue-a new role in humans? Nat Rev Endocrinol 6:319–325
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag/Wien
About this chapter
Cite this chapter
Stulnig, T.M., Zeyda, M. (2012). Adipokines, Inflammation, and Atherosclerosis. In: Wick, G., Grundtman, C. (eds) Inflammation and Atherosclerosis. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0338-8_14
Download citation
DOI: https://doi.org/10.1007/978-3-7091-0338-8_14
Published:
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-0337-1
Online ISBN: 978-3-7091-0338-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)